BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 23345607)

  • 1. A splicing twist on metastasis.
    Olson OC; Joyce JA
    Sci Transl Med; 2013 Jan; 5(169):169fs2. PubMed ID: 23345607
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KLF6-SV1 drives breast cancer metastasis and is associated with poor survival.
    Hatami R; Sieuwerts AM; Izadmehr S; Yao Z; Qiao RF; Papa L; Look MP; Smid M; Ohlssen J; Levine AC; Germain D; Burstein D; Kirschenbaum A; DiFeo A; Foekens JA; Narla G
    Sci Transl Med; 2013 Jan; 5(169):169ra12. PubMed ID: 23345610
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of KLF6 and its splice variants in cancer therapy.
    DiFeo A; Martignetti JA; Narla G
    Drug Resist Updat; 2009; 12(1-2):1-7. PubMed ID: 19097929
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of a novel alternative splicing transcript variant of the suppressor of fused: Relationship with lymph node metastasis in pancreatic ductal adenocarcinoma.
    Xu Q; Gao J; Li Z
    Int J Oncol; 2016 Dec; 49(6):2611-2619. PubMed ID: 27840902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of the mesenchymal-epithelial transition and its relationship with metastatic tumor formation.
    Yao D; Dai C; Peng S
    Mol Cancer Res; 2011 Dec; 9(12):1608-20. PubMed ID: 21840933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oncogenic splice variant of KLF6 as a prognostic marker in cancers.
    Khan MS; Bawany FI; Naeem M
    J Pak Med Assoc; 2013 Sep; 63(9):1215. PubMed ID: 24601213
    [No Abstract]   [Full Text] [Related]  

  • 7. ZNF217 is a marker of poor prognosis in breast cancer that drives epithelial-mesenchymal transition and invasion.
    Vendrell JA; Thollet A; Nguyen NT; Ghayad SE; Vinot S; Bièche I; Grisard E; Josserand V; Coll JL; Roux P; Corbo L; Treilleux I; Rimokh R; Cohen PA
    Cancer Res; 2012 Jul; 72(14):3593-606. PubMed ID: 22593193
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact.
    Foroni C; Broggini M; Generali D; Damia G
    Cancer Treat Rev; 2012 Oct; 38(6):689-97. PubMed ID: 22118888
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Screening of differential expression genes between primary breast cancer and its lymph node metastasis using single primer amplification of cDNA for microarray].
    Hao XS; Feng YM; Zhang L; Li XQ; Niu Y; Xiao CH; Sun BC
    Zhonghua Yi Xue Za Zhi; 2005 Feb; 85(6):385-90. PubMed ID: 15854527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The alternative splicing side of cancer.
    Biamonti G; Catillo M; Pignataro D; Montecucco A; Ghigna C
    Semin Cell Dev Biol; 2014 Aug; 32():30-6. PubMed ID: 24657195
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fibroblast growth factor receptor gene Arg388 allele is not associated with early lymph node metastasis of breast cancer.
    Becker N; Nieters A; Chang-Claude J
    Cancer Epidemiol Biomarkers Prev; 2003 Jun; 12(6):582-3. PubMed ID: 12815007
    [No Abstract]   [Full Text] [Related]  

  • 12. 15-Hydroxyprostaglandin dehydrogenase associates with poor prognosis in breast cancer, induces epithelial-mesenchymal transition, and promotes cell migration in cultured breast cancer cells.
    Lehtinen L; Vainio P; Wikman H; Reemts J; Hilvo M; Issa R; Pollari S; Brandt B; Oresic M; Pantel K; Kallioniemi O; Iljin K
    J Pathol; 2012 Mar; 226(4):674-86. PubMed ID: 22072156
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatoma-derived growth factor regulates breast cancer cell invasion by modulating epithelial--mesenchymal transition.
    Chen SC; Kung ML; Hu TH; Chen HY; Wu JC; Kuo HM; Tsai HE; Lin YW; Wen ZH; Liu JK; Yeh MH; Tai MH
    J Pathol; 2012 Oct; 228(2):158-69. PubMed ID: 22247069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. nm23 protein expression in fine-needle aspirates from breast carcinoma: inverse correlation with cytologic grading, lymph node status, and ploidy.
    Sauer T; Furu I; Beraki K; Jebsen PW; Ormerod E; Naess O
    Cancer; 1998 Apr; 84(2):109-14. PubMed ID: 9570214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Beyond lymph node staging: molecular predictors of outcome in breast cancer.
    Sheldon DG
    Surg Oncol Clin N Am; 2005 Jan; 14(1):69-84, vi. PubMed ID: 15542000
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hallmarks of alternative splicing in cancer.
    Oltean S; Bates DO
    Oncogene; 2014 Nov; 33(46):5311-8. PubMed ID: 24336324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical characteristics and prognostic factors of female breast cancer patients with 10 or more positive lymph nodes: a report of 128 patients].
    Guan Y; Xu BH; Li Q; Zhang P; Zhao LM; Yuan P; Wang JY
    Zhonghua Yi Xue Za Zhi; 2008 Jan; 88(2):77-81. PubMed ID: 18353207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical features and prognostic factors of small breast cancer with multiple axillary lymph node metastasis].
    Liao YQ; Xu BH
    Zhonghua Zhong Liu Za Zhi; 2007 Aug; 29(8):615-8. PubMed ID: 18210884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.
    Wang Y; Weng X; Wang L; Hao M; Li Y; Hou L; Liang Y; Wu T; Yao M; Lin G; Jiang Y; Fu G; Hou Z; Meng X; Lu J; Wang J
    J Clin Invest; 2018 Dec; 128(12):5235-5250. PubMed ID: 30204129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bcl-x(L)-mediated changes in metabolic pathways of breast cancer cells: from survival in the blood stream to organ-specific metastasis.
    España L; Martín B; Aragüés R; Chiva C; Oliva B; Andreu D; Sierra A
    Am J Pathol; 2005 Oct; 167(4):1125-37. PubMed ID: 16192647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.